Virtual Library
Start Your Search
- Virtual Library Home
- IASLC Library
- Explore Event
-
WCLC 2013
15th World Conference on Lung Cancer
Access to all presentations that occurred during the 15th World Conference on Lung Cancer in Sydney, Australia.
Presentation Date(s):- October 27 - 30, 2013
- Total Presentations: 2517
-
+
P1.11 - Poster Session 1 - NSCLC Novel Therapies
- Type: Poster Session
- Track: Medical Oncology
- Presentations: 45
- Coordinates: 10/28/2013, 09:30 - 16:30, Exhibit Hall, Ground Level
-
+
P1.11-024 - A phase I/II randomized trial using GM-CSF-producing and CD40L-expressing bystander cell line (GM.CD40L) vaccine plus or minus CCL21 in stage IV lung adenocarcinoma: Updated results
09:30 - 09:30 | Author(s): J.E. Gray
- Abstract
Loading...
-
+
MO05 - Prognostic and Predictive Biomarkers II
- Type: Mini Oral Abstract Session
- Track: Medical Oncology
- Presentations: 12
- Moderators:J. Hu
- Coordinates: 10/28/2013, 16:15 - 17:45, Parkside Auditorium, Level 1
-
+
MO05.03 - A gene expression platform to predict benefit from adjuvant external beam radiation in resected non-small cell lung cancer.
16:25 - 16:30 | Author(s): B.C. Creelan
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
P2.13 - Poster Session 2 - SCLC
- Type: Poster Session
- Track: Medical Oncology
- Presentations: 7
- Coordinates: 10/29/2013, 09:30 - 16:30, Exhibit Hall, Ground Level
-
+
P2.13-002 - Randomized Phase II Study of Single Agent OSI-906, an Oral, Small Molecule, Tyrosine Kinase Inhibitor (TKI) of the Insulin Growth Factor-1 Receptor (IGF-1R) Versus Topotecan for the Treatment of Patients with Relapsed Small Cell Lung Cancer (SCLC)
09:30 - 09:30 | Author(s): A.A. Chiappori
- Abstract
Loading...
-
+
O16 - NSCLC - Targeted Therapies III
- Type: Oral Abstract Session
- Track: Medical Oncology
- Presentations: 8
- Moderators:H.A. Wakelee
- Coordinates: 10/29/2013, 10:30 - 12:00, Parkside Auditorium, Level 1
-
+
O16.06 - A phase 1 dose escalation study of a new ALK inhibitor, CH5424802/RO5424802, in ALK+ Non-Small Cell Lung Cancer (NSCLC) patients who have failed crizotinib (AF-002JG/NP28761, NCT01588028).
11:25 - 11:35 | Author(s): S. Gadgeel
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
O16.07 - Consistent therapeutic efficacy of CH5424802/RO5424802 in brain metastases among crizotinib-refractory ALK-positive non-small cell lung cancer (NSCLC) patients in an ongoing phase I/II study (AF-002JG/NP28761, NCT01588028).
11:35 - 11:45 | Author(s): S.I. Ou
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.